Our Work
Latham & Watkins Advises Nevro in Cooperation Agreement With Engaged Capital
February 26, 2024
Firm’s shareholder activism defense team represented the global medical device company in agreement resulting in new board director appointment.
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC, pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors as well as the Audit Committee of the Board effective February 20, 2024.
Latham & Watkins LLP advised Nevro in connection with the cooperation agreement with a shareholder activism defense team led by partners Charles Ruck, Joshua Dubofsky, and Daniel Rees.